$50.24 -0.29 (%) Bristol Myers Squibb Co - NYSE

Oct. 2, 2014 | 02:02 PM

Partner Headlines

  1. Morgan Stanley Believes Bristol-Myers Squibb Co. Could Move Significantly Over Next Several Months

    Benzinga | Oct. 2, 2014 | 10:15AM EST
  2. Gilead's New HIV Drug Key To Long-Term Strategy

    IBD | Sep. 24, 2014 | 17:29PM EST
  3. Gilead OKs Generic Sovaldi To Expand Global Access

    IBD | Sep. 15, 2014 | 11:35AM EST
  4. Bristol-Myers Squibb Co In Patent Suit Vs. Merck & Co., Inc. Over Skin Cancer Drug

    Benzinga | Sep. 5, 2014 | 16:04PM EST
  5. Merck PD-1 Inhibitor Approved For Skin Cancer

    IBD | Sep. 4, 2014 | 16:33PM EST
  6. Drug M&A Boom Driven By Long-Term Trends: PwC

    IBD | Sep. 3, 2014 | 16:22PM EST
  7. Booming Biotech Market Benefits REIT BioMed Realty

    IBD | Sep. 2, 2014 | 17:42PM EST
  8. Bristol-Myers: Absolute Valuation Model versus Relative Valuation Model

    GuruFocus | Aug. 29, 2014 | 11:04AM EST
  9. Bristol-Myers Drug Gets OK

    IBD | Aug. 27, 2014 | 18:56PM EST
  10. Markets Little Changed In Low Volume And Slow News Ahead Of Long Weekend

    Benzinga | Aug. 27, 2014 | 17:17PM EST
  11. Deutsche Bank Starts Pfizer, Lilly at Buy, Merck, Bristol-Myers at Hold

    Benzinga | Aug. 27, 2014 | 12:32PM EST
  12. Bristol-Myers Hepatitis C Therapy Approved in EU

    IBD | Aug. 27, 2014 | 12:03PM EST
  13. US Stock Futures Edge Higher Ahead Of Tiffany Earnings

    Benzinga | Aug. 27, 2014 | 07:07AM EST
  14. Merck, Pfizer Combining Drugs In Lung Cancer Study

    IBD | Aug. 26, 2014 | 12:07PM EST
  15. Intercept Pharma Soars On Liver-Disease Drug Data

    IBD | Aug. 12, 2014 | 10:48AM EST
  16. Markets Marginally Higher On Light Volume And Encouraging Geopolitical Developments

    Benzinga | Aug. 11, 2014 | 16:46PM EST
  17. Drugmaker AstraZeneca Returns To Growth

    IBD | Aug. 5, 2014 | 17:22PM EST
  18. The Stocks Already in Correction Mode

    FoxBusiness | Aug. 1, 2014 | 08:15AM EST
  19. Will ImmunoGen's Q4 Earnings Disappoint Again?

    GuruFocus | Jul. 30, 2014 | 19:21PM EST
  20. Bristol-Myers surprises Street

    IBD | Jul. 24, 2014 | 18:57PM EST
  21. Thursday Morning Earnings Reports

    Benzinga | Jul. 24, 2014 | 12:14PM EST
  22. Stock Futures Steer Higher; Facebook, Skechers Nail Q2 Wins

    IBD | Jul. 24, 2014 | 09:09AM EST
  23. Earnings Scheduled For July 24, 2014

    Benzinga | Jul. 24, 2014 | 05:31AM EST
  24. Facebook, Gilead Headline IBD 50's Top 5 Earnings

    IBD | Jul. 19, 2014 | 08:02AM EST
  25. Benzinga Weekly Preview: Earnings Season Continues With Geopolitical Tensions As A Backdrop

    Benzinga | Jul. 18, 2014 | 16:47PM EST
  26. UnitedHealth Group Up on Weak Day for the Dow

    GuruFocus | Jul. 17, 2014 | 18:57PM EST
  27. Dow Sets New Intraday High; Citigroup Impresses With Earnings

    Benzinga | Jul. 14, 2014 | 16:44PM EST
  28. Senators Ask Gilead To Explain Sovaldi Pricing

    IBD | Jul. 11, 2014 | 11:35AM EST
  29. Bristol seeks cancer drug nod

    IBD | Jul. 10, 2014 | 18:45PM EST
  30. Bristol-Myers Seeking Nivolumab Approval In Melanoma

    IBD | Jul. 10, 2014 | 10:24AM EST
  31. Japan approves BMY regimen

    IBD | Jul. 7, 2014 | 18:58PM EST
  32. Jazz, Novo Among Medicals Showing Healthy Action

    IBD | Jul. 7, 2014 | 18:18PM EST
  33. Bristol-Myers' All-Oral HCV Therapy Approved In Japan

    IBD | Jul. 7, 2014 | 12:23PM EST
  34. Merck, Gilead Lead Race To Eradicate Hepatitis C

    IBD | Jul. 3, 2014 | 17:08PM EST
  35. Markets Little Changed Ahead Of 4th Of July Break

    Benzinga | Jul. 2, 2014 | 16:34PM EST
  36. Barclays Downgrades Pharmaceutical Sector

    Benzinga | Jul. 2, 2014 | 15:31PM EST
  37. UPDATE: Barclays Downgrades Bristol-Myers, Cuts Price Target By 41%

    Benzinga | Jul. 2, 2014 | 10:06AM EST
  38. Benzinga's Top Downgrades

    Benzinga | Jul. 2, 2014 | 08:01AM EST
  39. Ex-Dividends For July 1, 2014

    Benzinga | Jul. 1, 2014 | 09:44AM EST
  40. Pfizer and others get EU nods

    IBD | Jun. 27, 2014 | 18:37PM EST
  41. Bristol-Myers, Pfizer, Regeneron Drugs Get EU Nods

    IBD | Jun. 27, 2014 | 11:50AM EST
  42. Pfizer, Bristol-Myers Squibb Announce Positive Opinion For Treatments

    Benzinga | Jun. 27, 2014 | 09:36AM EST
  43. US Stock Futures Drop Ahead Of Consumer Sentiment Report

    Benzinga | Jun. 27, 2014 | 07:41AM EST
  44. Bristol-Myers Squibb Receives Positive CHMP Opinion for Daklinza for Treatment of Chronic Hepatitis C in the European Union

    Benzinga | Jun. 27, 2014 | 07:01AM EST
  45. Pharma Sector Stocks To Consider For Sustained Returns

    GuruFocus | Jun. 25, 2014 | 19:08PM EST
  46. Bristol-Myers Stock Up On Nivolumab Trial Success

    IBD | Jun. 25, 2014 | 11:11AM EST
  47. BRISTOL-MYERS SQUIBB

    IBD | Jun. 24, 2014 | 18:51PM EST
  48. UPDATE: Bristol Myers Announces Phase 3 First-Line Study of Nivolumab Stopped Early, Showed Superior Overall Survival vs Davarbazine

    Benzinga | Jun. 24, 2014 | 16:46PM EST
  49. Benzinga's M&A Chatter for Monday June 16, 2014

    Benzinga | Jun. 16, 2014 | 20:53PM EST
  50. Merck Takes The 'Nuc' Option In Hepatitis C Race

    IBD | Jun. 9, 2014 | 11:18AM EST
Trading Center